NEUPOGEN NEUPOGEN NEUTROMAX NEUTROMAX PDGRASTIM LEUCOSTIM GENELEUKIM GENELEUKIM GENELEUKIM GENELEUKIM GENELEUKIM GENELEUKIM FILATIL FILGEN TOPNEUTER TOPNEUTER FILGRAS NEUTROFIL SUN-GRAN SUN-GRAN GRASTIN NEULASTIM AUSPOGEN RH-GCSF RH-GCSF RH-GCSF JILFEN JILFEN

Dose: 5 ug/ kg
Single Dose: 5 (5)
Frequency: 24 hourly
Route: SC,IV Inf
Instructions: As an adjunct to chemotherapy, starting not less than 24 hrs after the last dose of antineoplstic.

Dose: 5 to 10 ug/kg
Single Dose: 7.5 (7.5)
Frequency: 24 hourly
Route: Oral
Instructions: Forr 3----5 days

. It is of Semi Synthetic origin and belongs to Polypeptide. It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action and also classified in Hematological Agents and Colony Stimulating Factor pharmacological group.The Molecular Weight of Filgrastim is 18799.00. It is weakly acidic drug.

Filgrastim is contraindicated in conditions like Myeloblastic leukemia.

The severe or irreversible adverse effects of Filgrastim, which give rise to further complications include Vasculitis, Myelogenous leukemia, Leukocytoclastic, Neutrophillic dermatitis.Filgrastim produces potentially life-threatening effects which include Proliferation of myelogenous cells, Leukemic crisis. which are responsible for the discontinuation of Filgrastim therapy.The signs and symptoms that are produced after the acute overdosage of Filgrastim include Bone pain, Elevation of alkaline phosphatase, Elevation of LDH.The symptomatic adverse reactions produced by Filgrastim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Fever, Skin rash, Medullary bone pain.

Filgrastim is primarily indicated in conditions like Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Myeloablative therapy followed by bone marrow transplantation, Neutropenia, Persistant neutropenia in advanced hiv infection, Severe chronic neutropenia, and can also be given in adjunctive therapy as an alternative drug of choice in AIDS, Aplastic anemia, Myelodysplastic syndrome.

Filgrastim is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementBleomycinCoadministration is not recommended because hematopoietic growth factors stimulate myeloid cell poliferation while cytotoxic agents target rapidly dividing cell.Leads to pulmonary toxicity.ModerateFilgrastim should not be used within 24 hours before or 24 hours after bleomycin.MitotaneThe safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cytotoxic chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while cytotoxic agents primarily target rapidly dividing cells.ModerateBecause of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after cytotoxic chemotherapy administration. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj (reconstituted soln) Store in refrigerator. Do not Freeze. Protect from Sunlight. Use within 24 hrs if kept at room temperature.

Filgrastim should be used only if clearly needed during pregnancy. It should be used with caution in patients with any pre-existing heart disease or any allergies.